Logo

Genome Therapeutics And Schering-Plough Extend Collaboration

Dec 21, 1998
Premium

WALTHAM, Mass.--Genome Therapeutics here announced the extension of its $43.5 million collaboration with Schering-Plough to identify and develop novel antiinfectives for drug-resistant bacteria. The expanded agreement will carry the alliance at least through March 31, 2000. The two companies also forged a $67 million alliance in December, 1996, to develop novel therapeutics for asthma, and a $33 million antifungal collaboration in September, 1997.

Genome Therapeutics' commercial gene discovery strategy is to identify and characterize human genes associated with major diseases and to elucidate bacterial genes responsible for many serious infectious diseases.

Filed under

Informatics
Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.